<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-214183933-1"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-214183933-1');
    </script>

    <!-- Bootstrap CSS -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-1BmE4kWBq78iYhFldvKuhfTAU6auU8tT94WrHftjDbrCEXSU1oBoqyl2QvZ6jIW3" crossorigin="anonymous">

    <style type="text/css">
      table {
        font-size: small;
      }
      a {
        color: grey;
      }
      a:link {
        text-decoration: none;
      }
      a:hover {
        text-decoration: underline;
      }
      p {
        text-align: justify;
      }
      th {white-space: nowrap;}
      td:nth-child(2)  {white-space: nowrap;}

      /* styling buttons */
      .show-more-btn {
        margin-bottom: 15px;
        cursor: pointer;
        color: #0095e5;
        white-space: nowrap;
        transition: color 300ms ease-in-out;
        border: 0;
        font-size: small;
        background: transparent;
      }
      .show-more-btn:hover {
        color: red;
      }
      .hidden {
        display: none;
      }
    </style>
    <script src="https://cdn.jsdelivr.net/gh/tomik23/show-more@1.1.2/dist/js/showMore.min.js"></script>

    <script type="text/javascript">
      document.addEventListener('DOMContentLoaded', function () {
        // text, table, list, elelemnts
        new ShowMore('.element', {
          onMoreLess: (type, object) => {
            // type = less/more and full object
            console.log(type, object);
          },
        });
      });
    </script>

    <title>Brayniac</title>
  </head>
  <body>
    <div class="container justify-content-center mt-5">
      <div class="col-xxl-8 col-xl-10 col-md-12 mx-auto">
        <div class="row border-bottom mb-4 pb-4">
          <h1 class="mb-5">Fierce Biotech</h1>
          <p>
            Brayniac read 100 webpages. This content is about 37 pages long.
          </p>
          <p>
            Brayniac generated a list of keywords on the left and corresponding blurbs on the right. The keywords are ranked by importance. The most important keyword appears at the top. As you scroll down, the keyword importance decreases.
          </p>
          <p>
            The blurb include an actual usage of the keyword from the webpages. It also provides a breakdown of which posts and how many times the keyword appeared in those posts.
          </p>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Life Sciences Events                                                                       Connect</h3></div>
          <div class="col-9">
            <p>Life Sciences Events                                                                       Connect     The Team    Advertise      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Life Sciences Events</h3></div>
          <div class="col-9">
            <p>Life Sciences Events                                        Research     Biotech    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Fierce Biotech</h3></div>
          <div class="col-9">
            <p>Fierce Biotech     Fierce Healthcare    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Fierce Healthcare</h3></div>
          <div class="col-9">
            <p>Fierce Healthcare     Life Sciences Events                                        Research    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Life Sciences Events                                        Research</h3></div>
          <div class="col-9">
            <p>Life Sciences Events                                        Research     Biotech    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Biotech</h3></div>
          <div class="col-9">
            <p>Fierce Biotech     Fierce Healthcare    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Data</h3></div>
          <div class="col-9">
            <p>Clinical Data     Venture Capital    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Venture Capital</h3></div>
          <div class="col-9">
            <p>Venture Capital     Deals      Medtech    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Medtech    </h3></div>
          <div class="col-9">
            <p>Deals      Medtech     Devices      CRO    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Trending Topics    </h3></div>
          <div class="col-9">
            <p>Trending Topics     Cell & Gene Therapy    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Cell & Gene Therapy</h3></div>
          <div class="col-9">
            <p>Cell & Gene Therapy     COVID-19    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Emerging Biopharma</h3></div>
          <div class="col-9">
            <p>Oncology    Emerging Biopharma     Decentralized Trials          </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Decentralized Trials</h3></div>
          <div class="col-9">
            <p>Decentralized Trials           Resources    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Subscribe</h3></div>
          <div class="col-9">
            <p>Webinars      Subscribe                      What are you searching for?                  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Fierce Pharma</h3></div>
          <div class="col-9">
            <p>                                                      Fierce Pharma     Fierce Biotech    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>The Team    Advertise</h3></div>
          <div class="col-9">
            <p>The Team    Advertise       Join Us    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Join Us    </h3></div>
          <div class="col-9">
            <p>Join Us     Newsletters    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>RSS Feeds</h3></div>
          <div class="col-9">
            <p>RSS Feeds       Our Brands    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Our Brands    </h3></div>
          <div class="col-9">
            <p>Our Brands     Fierce Pharma    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Life Sciences Events                     ©</h3></div>
          <div class="col-9">
            <p>Life Sciences Events                     ©2022 Questex LLC</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Questex LLC</h3></div>
          <div class="col-9">
            <p>Questex LLC All rights reserved.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">2020-07-21</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/tubulis-raises-a-round-to-advance-next-gen-adc-programs">Tubulis raises A round to advance next-gen ADC programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pyxis-debuts-next-gen-adcs-from-under-pfizer-s-wing">Pyxis debuts next-gen cancer ADCs from under Pfizer's wing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-gets-priority-review-for-anti-cd19-blood-cancer-drug">ADC gets priority review for anti-CD19 blood cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-to-pay-seattle-genetics-1-6b-to-ally-breast-cancer-adc">Merck to pay Seattle $1.6B for ADC work as ex-partner Immunomedics nabs the big bucks buyout | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-09-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-nets-85m-top-up-to-push-lead-adc-through-phase-1">Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies">With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-12-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mystery-no-more-mythic-therapeutics-emerges-103m-to-test-antibody-drug-conjugates-lung">Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets">J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc">Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-11-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-lines-up-fda-filing-as-antibody-drug-conjugate-shrinks-tumors-pivotal-trial">ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-s-adc-misses-endpoint-ovarian-cancer-phase-3">ImmunoGen’s ADC misses endpoint in ovarian cancer phase 3 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/cancer-research-technology-and-adc-therapeutics-join-forces-on-antibody-drug-conjugates">Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/keyword/adc-therapeutics">ADC Therapeutics | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race">Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=0">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-07-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-nets-85-4m-to-drive-antibody-drug-conjugates">Sutro Biopharma nets $85.4M to drive antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-03-26</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/celtic-therapeutics-launches-50m-antibody-drug-conjugates-development-company-10-adc">Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-05-17</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glioblastoma-claims-another-pharma-victim-as-abbvie-s-adc-fails-to-boost-survival">Glioblastoma claims another pharma victim as AbbVie's ADC fails to boost survival  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-01-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-axes-60-person-plexxikon-r-d-facility-california-to-free-up-cash-for-adc">Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-08-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-biopharma-eyes-75m-ipo-to-push-antibody-drug-conjugates">Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2022-02-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/lilly-reunites-immunogen-expand-adcs-paying-13m-upfront-and-17b-backend">Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adct-says-decision-to-pull-her2-drug-doesn-t-affect-other-candidates">ADCT says decision to pull HER2 drug doesn’t affect other candidates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-12-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sutro-s-antibody-drug-conjugate-impresses-hard-to-treat-ovarian-cancer">Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc">Patient death prompts FDA hold on Mersana’s lead cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b">After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/adc-therapeutics-top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-oxford-biotherapeutics-to-collaborate-on-antibody-drug-conjugates-for">Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/shanghai-miracogen-taps-synaffix-s-antibody-drug-conjugate-tech-a-deal-worth-up-to-125m">Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to $125M | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against">ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling">What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/piramal-s-healthcare-vertical-invests-usd-2-5-million-to-further-expand-commercial-adc-capacity">Piramal's healthcare vertical invests USD $2.5 million to further expand  commercial ADC capacity | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/avrobio-taps-magenta-s-adc-for-gene-therapy-conditioning">Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-05-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-gets-30m-amid-sanofi-adc-deal-shake-up">ImmunoGen gets $30M amid Sanofi ADC deal shake-up | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/sabcs-astrazeneca-daiichi-s-adc-keeps-breast-cancer-at-bay-for-16-months">SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline">Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-gets-q2-2020-pdufa-date-for-breast-cancer-adc">AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/abbott-doubles-down-on-adc-cancer-drugs-245m-plus-seattle-genetics-pact">Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-03-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/china-startup-suzhou-medilink-therapeutics-nabs-50m-for-hot-r-d-cancer-field">China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-07-15</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibody-from-bzl-biologics-for-prostate-cancer">ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-ditches-antibody-drug-conjugate-after-early-phase-fizzle">Genmab ditches antibody-drug conjugate after early-phase fizzle | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/daiichi-sankyo-wants-glycotope-lead-antibody-for-cancer-adc">Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/glythera-rebrands-as-iksuda-pledging-to-solve-adc-problems">Glythera rebrands as Iksuda, pledging to solve ADC problems | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-enters-into-new-antibody-drug-conjugate-collaboration-bayer">Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-04-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/one-ipo-attempt-pulled-a-drug-partial-hold-and-a-pandemic-but-adc-tx-tries-again">One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-03</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors">ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-bets-1b-daiichi-rival-to-immunomedics-trodelvy">AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-06-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-second">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Ex | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-10-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-helps-adct-to-200m-mega-round-to-push-anti-cancer-adcs-to-pivotal-data">AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-03-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-puts-6-9b-table-for-a-daiichi-sankyo-cancer-drug">AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing">ADC Therapeutics bumps up series E by $76M, prepares lead drug for 2020 filing | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-bcma-drug-after-seeing-early-clinical-data">AstraZeneca drops BCMA drug after seeing early clinical data | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-tees-up-100m-ipo-to-push-adcs-for-cancer-hep-b">Silverback tees up $100M IPO to push ADCs for cancer, hep B | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-12-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/phase-2-data-for-roche-s-lymphoma-adc-doesn-t-disappoint">Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-01-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/synthon-biopharmaceuticals-reports-positive-early-results-its-second-generation-her2">Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/topic/antibody-drug-conjugates?page=7">antibody-drug conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-11-09</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-a-novel-immuno-oncology-chemotherapy-combo-treatment">Attacking pancreatic cancer with a novel immuno-oncology drug conjugate | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-09-20</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/bankrolled-by-pfizer-and-bayer-pyxis-files-for-100m-ipo-to-take-cancer-drugs-into-clinic">Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-12</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/attacking-pancreatic-cancer-by-recruiting-foot-and-mouth-disease-virus">Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-and-merck-kgaa-of-darmstadt-germany-to-develop-next-generation-antibody-drug">Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/biotecnol-and-polytherics-enter-into-a-research-collaboration-for-development-of-tribody">Biotecnol and PolyTherics enter into a Research Collaboration for the Development of 'Tribody' Antibody Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/emd-serono-and-mersana-to-develop-next-generation-antibody-drug-conjugates">EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/genmab-buys-idd-antibody-assets-drops-adc-co-development-rights">Genmab buys iDD antibody assets, drops ADC co-development rights | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/five-prime-grabs-5m-lifeline-seattle-genetics-adc-deal">Five Prime grabs $5M lifeline in Seattle Genetics ADC deal  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-06-30</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data">Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-04-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020">The top 15 biopharma licensing deals of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-06-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/iksuda-raises-47m-to-take-cd19-antibody-drug-conjugate-into-clinic">Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-07-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/astellas-winds-down-agensys-turning-its-back-antibody-drug-conjugate-research">Astellas winds down Agensys, turning its back on antibody-drug conjugate research | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-09-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-genmab-enter-into-new-antibody-drug-conjugate-collaboration">Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-06-24</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/mersana-grabs-a-792m-adc-development-pact-merck-kgaa">Mersana grabs a $792M ADC development pact with Merck KGaA | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-appoints-former-genmab-vp-dr-patrick-van-berkel-as-senior-vp-of-r-d">ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-06-25</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/cro/novasep-invests-%E2%82%AC10m-to-reinforce-its-bioconjugation-services">Novasep invests €10M to reinforce its bioconjugation services | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-11-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an">ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-02-16</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2020">The top 10 biotech IPOs of 2020 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-07-02</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/pfizer-backed-bolt-therapeutics-strikes-93-5m-funding-round-as-lead-med-hits-clinic">Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-scores-208m-pfizer-pact-for-adc-tech">Seattle Genetics scores $208M Pfizer pact for ADC tech | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-10</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestones-as-genentech-advances-two-antibody-drug-conjugates">Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-strikes-again-208m-adc-deal-abbott">Seattle Genetics strikes again with $208M ADC deal with Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-04-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-enters-collaboration-takeda-to-develop-next-generation-antibody-drug">Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-19</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/genmab-retains-partial-rights-for-humax-tac-adc-%E2%80%94-will-not-exercise-co-development-right">Genmab Retains Partial Rights for HuMax-TAC-ADC — Will Not Exercise Co-development Right | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-04-05</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/astellas-ambrx-seal-300m-cancer-adc-deal">Astellas, Ambrx seal $300M cancer ADC deal | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-10-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/partnering/immunogen-bags-adc-deal-novartis">ImmunoGen bags ADC deal with Novartis | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2014-01-08</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-further-expands-antibody-drug-conjugate-collaboration-abbvie">Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/boehringer-backs-20m-round-adc-cancer-player">Boehringer backs $20M round in ADC cancer player  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial">ImmunoGen cuts deep to eke out cash for mirvetuximab trial | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-07-31</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates">Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2021-10-07</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy">Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2019-02-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc">Crunch time for ImmunoGen as phase 3 readout looms for lead ADC | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-04</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/financials/europe-s-leading-meeting-for-bioprocessing-announces-biosimilars-antibody-drug">Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013 | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-03-11</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/silverback-therapeutics-bags-79m-to-push-antibody-drug-conjugate-into-clinic">Silverback Therapeutics bags $79M to push antibody-drug conjugate into clinic   | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-02-14</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunomedics-nabs-j-j-veteran-for-cmo-as-it-presses-adc-redo">Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/research/seattle-genetics-highlights-next-generation-antibody-drug-conjugate-sgn-cd33a-at-ash">Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A At ASH Annual Meeting | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2018-06-28</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/adc-startup-nbe-raises-20m-from-novo-holdings-doubling-size-boeheringer-backed-b-round">ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2008-06-18</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-achieves-milestone-under-antibody-drug-conjugate-collaboration-triggered">Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2012-10-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/menarini-commits-itself-to-1b-cancer-adc-deal-oxford-biotherapeutics">Menarini commits itself to $1B cancer ADC deal with Oxford BioTherapeutics  | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2015-03-23</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/immunogen-strikes-440m-adc-deal-takeda">ImmunoGen strikes $440M ADC deal with Takeda | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2013-06-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-and-agensys-an-affiliate-of-astellas-announce-co-development-of-an">Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2017-08-29</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/jazz-pays-75m-for-chance-to-buy-into-immunogen-adcs">Jazz pays $75M for chance to buy into ImmunoGen ADCs | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2020-05-27</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision">ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-03-22</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-abbott-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Abbott | Fierce Biotech</a></td>
                </tr>
    
                <tr>
                  <th scope="row">2011-01-06</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://www.fiercebiotech.com/biotech/seattle-genetics-announces-antibody-drug-conjugate-collaboration-pfizer-0">Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with       Pfizer | Fierce Biotech</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
        </div><!-- Outer col -->
    </div><!-- Container -->
    <!-- Option 1: Bootstrap Bundle with Popper -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js/bootstrap.bundle.min.js" integrity="sha384-ka7Sk0Gln4gmtz2MlQnikT1wXgYsOg+OMhuP+IlRH9sENBO0LRn5q+8nbTov4+1p" crossorigin="anonymous"></script>
  </body>
</html>
  